The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

23andMe’s first patent on gene variant for Parkinson’s disease raises hopes, hackles

The recent news of 23andMe’s first patent shows how patents on natural genes continue despite the complex legal situation faced by other companies, and despite an explicitly stated ethos of openness and “democratization.” 23andMe has patented methods for screening the naturally occurring variants of the human genome they found to be associated with risk for Parkinson’s disease. The announcement on the company’s blog, The Spittoon, clarifies what they hope the patent will and won’t do.

Additional Resources:

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.

Comments are closed.

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend